Magenta Therapeutics, Inc.
Compositions and methods for the depletion of CD137+ cells

Last updated:

Abstract:

The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.

Status:
Grant
Type:

Utility

Filling date:

19 Jan 2018

Issue date:

3 Mar 2020